Investors

About NeuroSense

NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people with ALS, as well as other neurodegenerative diseases. We are focused on creating a combined therapeutic strategy, targeting the multiple pertinent mechanisms in these complex diseases.

PrimeC, our lead therapeutic candidate for ALS, has been granted orphan drug designation by the FDA and EMA, and has been tested successfully in a phase 2a study. Preparations are underway for a pivotal phase II/3 clinical trial in ALS.
Additionally, we are currently expanding our pipeline and are initiating preclinical studies in additional neurodegenerative indications for PrimeC.
We invite you to take part in our program and accelerate the clinical development toward a cure for ALS and other neurodegenerative diseases.

Investment in NeuroSense

To date, there is no effective drug for ALS. The available treatments in the market can slightly moderate disease progression, or delay death by only a few months.
NeuroSense’s drug in development, PrimeC, targets multiple pathological mechanisms simultaneously and works synergistically to slow and perhaps halt disease progression.

We welcome you to contact below or call us at: +972-587-531153

Key Investment Merits

Short Time to Market, and Known Safety Profiles

Excellent ALS Pre-clinical Results

Promising Clinical Trends in ALS Patients

Bright and Passionate Minds Motivated to the Cause

Non-invasive Treatment

Addressing Several Pertinent Targets

Further Neurodegenerative Indications

Orphan Drug Incentives

Why Invest in NeuroSense?

Market and Competition

The market for an effective drug that can stop or significantly slow ALS disease progression is estimated at billions of dollars. There are an estimated 70,000 ALS patients in the western world, and 450,000 patients worldwide. The average cost per year for patients in the U.S. in late stages of the disease are estimated at $300,000.
Several other companies are at different stages of drug development for ALS. These include: Cytokinetics, Biogen, AB Science, Kadimastem, Immunity Pharma and Amylyx.

Disease Modifying Treatment vs. Symptomatic Treatment

Many of the available drugs and treatments in development today for ALS address merely the symptoms of the disease, and grant patients only a few extra months of functionality. NeuroSense’s novel drug aims to drastically slow or even halt disease progression, hence increasing patients’ life expectancy and improving quality of life.

Molecular Mechanisms vs. Stem Cells

In contrast to other companies, which focus on stem cell treatments aimed at affecting the system as a whole, NeuroSense emphasizes the multifarious underlying pathological and molecular mechanisms of the disease in order to pinpoint the treatment effect.

Pain-Free vs. Invasive Treatment

Many of the treatments being developed for ALS patients are invasive, and include extraction and/or injection of cells or other types of infusions. NeuroSense’s drug is a small, easy-to-use pill to be swallowed.